Compare IDEXX Laboratories, Inc. (IDXX) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Impinj Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518.59 (market cap $40.43B), while Impinj Inc trades at $187.46 (market cap $5.60B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.2× Impinj Inc's market cap, and Impinj Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Impinj Inc for 22 Days on average.
| IDXX | PI | |
|---|---|---|
Market Cap | $40.43B | $5.60B |
Volume | 692,164 | 9,929 |
Sector | Health | Technology |
52-Week High | $766.68 | $241.91 |
52-Week Low | $504.70 | $91.34 |
Typical Hold Time | 46 Days | 22 Days |
Enterprise Value | $41.32B | $5.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Impinj (PI) trades at $186.53, down 2.36% with a bullish technical outlook despite negative profitability metrics. The stock shows strong analyst support with 16 buy ratings and a $178.83 consensus target. Recent Q2 2026 earnings beat expectations with $0.86 EPS, while revenue growth continues but net margins remain negative at -7.26%. The company maintains solid cash flow from operations of $58.75M in 2025.
Investment outlook balances growth potential against profitability challenges. The RAIN RFID technology market offers expansion opportunities, but elevated valuations (P/S 14.83) and negative ROE (-12.87%) present risks. Near-term catalysts include Q3 2026 results, while competitive pressures and execution risks require monitoring for sustained shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
